1. Home
  2. WRBY vs MLYS Comparison

WRBY vs MLYS Comparison

Compare WRBY & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Warby Parker Inc.

WRBY

Warby Parker Inc.

HOLD

Current Price

$27.10

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$35.11

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WRBY
MLYS
Founded
2010
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Ophthalmic Goods
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
3.1B
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
WRBY
MLYS
Price
$27.10
$35.11
Analyst Decision
Buy
Strong Buy
Analyst Count
15
7
Target Price
$25.43
$47.33
AVG Volume (30 Days)
6.2M
1.5M
Earning Date
02-26-2026
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.00
N/A
Revenue
$850,580,000.00
N/A
Revenue This Year
$15.47
N/A
Revenue Next Year
$13.06
N/A
P/E Ratio
$10,438.63
N/A
Revenue Growth
14.55
N/A
52 Week Low
$13.63
$8.24
52 Week High
$31.00
$47.65

Technical Indicators

Market Signals
Indicator
WRBY
MLYS
Relative Strength Index (RSI) 62.66 36.49
Support Level $21.46 $34.21
Resistance Level $27.29 $36.61
Average True Range (ATR) 1.38 1.49
MACD -0.14 -0.02
Stochastic Oscillator 86.00 24.58

Price Performance

Historical Comparison
WRBY
MLYS

About WRBY Warby Parker Inc.

Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: